Alfredo Damasceno1, Benito Pereira Damasceno2, Fernando Cendes2. 1. Departamento de Neurologia, Rua Tessália Vieira de Camargo, Universitária Zeferino Vaz, Brazil alfredodamasceno@hotmail.com. 2. Department of Neurology, University of Campinas (UNICAMP), Brazil.
Abstract
BACKGROUND: The concept of no evidence of disease activity (NEDA) has emerged as an important outcome measure for multiple sclerosis (MS). However, it is not known if maintaining NEDA has a positive impact on cognition or brain atrophy. OBJECTIVE: To evaluate NEDA status after two years, addressing its implications on cognition and brain atrophy. METHODS: Forty-two relapsing-remitting MS patients and 30 controls underwent MRI (3T) and cognitive evaluation (BRB-N). Forty patients performed additional evaluations, after 12 and 24 months. NEDA was defined as the absence of clinical (relapses/disability progression) and MRI activity (new T2/gadolinium-enhancing lesions). Repeated measures and multivariate analyses were performed to assess the contribution of NEDA criteria to GM atrophy. RESULTS: After two years, 30.8% of the cohort had NEDA. From these, 58.3% still had worsening in ⩾2 cognitive domains. Patients with MRI activity had more cortical thinning and slightly more thalamus volume decrease. Absence of new/enlarging T2 lesions was the only predictor of cortical thinning, subcortical GM and thalamic atrophy rates. CONCLUSIONS: NEDA status was achieved in a small proportion of our cohort, and did not preclude cognitive deterioration. Absence of MRI activity and especially of new/enlarging T2 lesions was associated with less cortical and subcortical GM atrophy.
BACKGROUND: The concept of no evidence of disease activity (NEDA) has emerged as an important outcome measure for multiple sclerosis (MS). However, it is not known if maintaining NEDA has a positive impact on cognition or brain atrophy. OBJECTIVE: To evaluate NEDA status after two years, addressing its implications on cognition and brain atrophy. METHODS: Forty-two relapsing-remitting MSpatients and 30 controls underwent MRI (3T) and cognitive evaluation (BRB-N). Forty patients performed additional evaluations, after 12 and 24 months. NEDA was defined as the absence of clinical (relapses/disability progression) and MRI activity (new T2/gadolinium-enhancing lesions). Repeated measures and multivariate analyses were performed to assess the contribution of NEDA criteria to GMatrophy. RESULTS: After two years, 30.8% of the cohort had NEDA. From these, 58.3% still had worsening in ⩾2 cognitive domains. Patients with MRI activity had more cortical thinning and slightly more thalamus volume decrease. Absence of new/enlarging T2 lesions was the only predictor of cortical thinning, subcortical GM and thalamic atrophy rates. CONCLUSIONS:NEDA status was achieved in a small proportion of our cohort, and did not preclude cognitive deterioration. Absence of MRI activity and especially of new/enlarging T2 lesions was associated with less cortical and subcortical GM atrophy.
Authors: Richard L Doty; Michael R MacGillivray; Hussam Talab; Isabelle Tourbier; Megan Reish; Sherrie Davis; Jennifer L Cuzzocreo; Neil T Shepard; Dzung L Pham Journal: Exp Brain Res Date: 2018-07-17 Impact factor: 1.972
Authors: Maria A Rocca; Marco Battaglini; Ralph H B Benedict; Nicola De Stefano; Jeroen J G Geurts; Roland G Henry; Mark A Horsfield; Mark Jenkinson; Elisabetta Pagani; Massimo Filippi Journal: Neurology Date: 2016-12-16 Impact factor: 9.910
Authors: Ricardo N Alonso; Maria B Eizaguirre; Berenice Silva; Maria C Pita; Cecilia Yastremiz; Sandra Vanotti; Fernando Cáceres; Orlando Garcea Journal: Int J MS Care Date: 2020 Jan-Feb
Authors: Ralph Hb Benedict; John DeLuca; Glenn Phillips; Nicholas LaRocca; Lynn D Hudson; Richard Rudick Journal: Mult Scler Date: 2017-02-16 Impact factor: 6.312